Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the ...
Zacks Investment Research on MSN
AstraZeneca gets accelerated FDA nod for Ultomiris in IgA nephropathy
AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...
With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Get the detailed balance sheet for Travere Therapeutics, Inc. (TVTX). Up to 10 years of financial statements. Quarterly or ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The FDA has approved Ultomiris to reduce proteinuria in adult patients with primary immunoglobulin A, or IgA, nephropathy who ...
Avviso esplicito sui rischi: Il trading degli strumenti finanziari e/o di criptovalute comporta alti rischi, compreso quello ...
2026年秋意正浓，资本市场的风向标却早已悄然转向——不是白酒，不是新能源，也不是AI算力芯片，而是藏在实验室冻存管与临床中心CT室之间的那群‘分子猎手’。就在10月16日，证券之星独家披露了一则看似平淡、实则暗流汹涌的机构调研动态：成立仅8年的惠升基金，悄然奔赴苏州工业园区，对创新药企信诺维（688527.SH）展开深度调研。这不是一次普通拜访，而是一场面向未来三年医药赛道胜负手的战略侦察。 没 ...
阿斯特捷利康 (AZN) 盤中上漲3.04%，所屬行業 醫藥與醫學研究 上漲1.42%，公司漲幅跑贏行業漲幅，行業成交額前三股票 Moderna Inc (MRNA) 下跌 24.58%； Eli Lilly and Co (LLY) 上漲 3.16 ...
【2026年10月17日·财经热搜榜TOP3】当全市场还在为‘AI算力荒’焦头烂额时，一只管理规模破1.23万亿元的‘国民基民首选’——天弘基金，已悄然完成一轮高密度、高含金量的战略踩点。就在刚刚过去的10月16日，证券之星独家披露：天弘基金于三季度末至10月中旬密集调研3家A股硬核标的——神州数码、信诺维、天孚通信。这不是普通走马观花的‘打卡式调研’，而是一场横跨AI基建、智能医疗、光通信与全球 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results